These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 6586292)
1. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. Edwards BS; Hawkins MJ; Borden EC Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292 [TBL] [Abstract][Full Text] [Related]
2. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity. Edwards BS; Hawkins MJ; Borden EC J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345 [TBL] [Abstract][Full Text] [Related]
3. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A. Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351 [TBL] [Abstract][Full Text] [Related]
4. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Brunda MJ; Rosenbaum D Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364 [TBL] [Abstract][Full Text] [Related]
5. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon. Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490 [TBL] [Abstract][Full Text] [Related]
6. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Verhagen A; Mackay IR; Rowley M; Tymms M Nat Immun Cell Growth Regul; 1990; 9(5):325-33. PubMed ID: 2077397 [TBL] [Abstract][Full Text] [Related]
7. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients. Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067 [TBL] [Abstract][Full Text] [Related]
8. Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes. Lee SH; Kelley S; Chiu H; Stebbing N Cancer Res; 1982 Apr; 42(4):1312-6. PubMed ID: 6174222 [TBL] [Abstract][Full Text] [Related]
9. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients. Koren HS; Brandt CP; Tso CY; Laszlo J J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332 [TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204 [TBL] [Abstract][Full Text] [Related]
11. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J. Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813 [TBL] [Abstract][Full Text] [Related]
12. Augmentation of human natural killer cell activity by cyclophosphamide in vitro. Sharma B; Vaziri ND Cancer Res; 1984 Aug; 44(8):3258-61. PubMed ID: 6589041 [TBL] [Abstract][Full Text] [Related]
13. The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells. Okabe M; Gomi K; Morimoto M; Nakamizo N Jpn J Cancer Res; 1985 Jul; 76(7):608-17. PubMed ID: 3928557 [TBL] [Abstract][Full Text] [Related]
14. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197 [TBL] [Abstract][Full Text] [Related]
15. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy. Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350 [TBL] [Abstract][Full Text] [Related]
16. Impaired in vitro interferon, blastogenic, and natural killer cell responses to viral stimulation in acquired immune deficiency syndrome. Hersh EM; Gutterman JU; Spector S; Friedman H; Greenberg SB; Reuben JM; LaPushin R; Matza M; Mansell PW Cancer Res; 1985 Jan; 45(1):406-10. PubMed ID: 2578099 [TBL] [Abstract][Full Text] [Related]
17. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
18. In vitro enhancement of peripheral blood mononuclear cell natural killer activity following short term incubation with fetal calf serum. Lauer SJ; Finlan J; Borella LD; Piaskowski VD; Casper JT J Clin Lab Immunol; 1983 Oct; 12(2):105-10. PubMed ID: 6606047 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of interferon-alpha 2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome. Reddy MM; Chinoy P; Grieco MH J Biol Response Mod; 1984 Aug; 3(4):379-86. PubMed ID: 6332880 [TBL] [Abstract][Full Text] [Related]
20. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines. Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]